Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly identifies Yervoy as ipilimumab and describes a CTLA-4–mediated immune mechanism, including an immunotherapy-like interpretation. It makes an unsupported indication claim and omits critical safety and dosing information present in the label.
Category Scores
Accurate Statements
Yervoy works by boosting the body's immune system to fight cancer cells.
12.1
Yervoy is a type of immunotherapy.
12.1
Unsupported Statements
Ipilimumab is a medication used to treat certain types of cancer, including melanoma, lung cancer, and kidney cancer.
Indications are not provided in the excerpt; the label’s Indications and Usage content shown does not include explicit cancer types in the provided text.
Contradictions
Important Omissions
Boxed warning for immune-mediated adverse reactions (Warnings and Precautions).
Importance:
Critical
Dosing and administration details.
Importance:
Critical
Pregnancy risk (8.1) information.
Importance:
Critical
Pediatric safety/use (8.4).
Importance:
High
Contraindications (Section 4).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims focus on mechanism and identity;missing safety details (boxed warnings, dosing, pregnancy/pediatric considerations, and contraindications) elevate risk if used for clinical decision-making.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication claim is unsupported; critical safety and dosing information omitted.
Suggested Improvement
Align claims with label by confirming Indications in Section 1, and include boxed warnings, dosing/administration guidelines, pregnancy and pediatric use, and contraindications. Provide explicit label section citations.